Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Jijun Yuan"'
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high mortality, and there are no uniform guidelines for the treatment of this disease. Anti-CD19 chimeric antigen receptor (CAR) T cells show significant efficacy in
Externí odkaz:
https://doaj.org/article/6cb0804e4b9a472e8af9e3d30f1c9b01
Autor:
Haobin Deng, Meijing Liu, Ting Yuan, Huan Zhang, Rui Cui, Jingyi Li, Jijun Yuan, Xiaofang Wang, Yafei Wang, Qi Deng
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
In recent years, many new treatments for relapsed/refractory (R/R) multiple myeloma (MM) have improved patient prognosis, but the prognosis of patients with extramedullary MM is still particularly poor. Therefore, more efficacious therapies and novel
Externí odkaz:
https://doaj.org/article/bb6183acb79148fc947f850217dd40b3
Autor:
Juan Mu, Haobin Deng, Cuicui Lyu, Jijun Yuan, Qing Li, Jia Wang, Yanyu Jiang, Qi Deng, Jichun Shen
Publikováno v:
Hematological oncologyREFERENCES.
We studied the efficacy and safety of the combined treatment with programmed cell death 1 (PD-1) inhibitors and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and subsequent PD-1 inhibitor maintenance treatment in patients with relapsed/ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d62c26ef48de3a78af325fd78f7ac3e
https://pubmed.ncbi.nlm.nih.gov/35195933
https://pubmed.ncbi.nlm.nih.gov/35195933
Autor:
null Juan Mu, null Haobin Deng, null Cuicui Lyu, null Jijun Yuan, null Qing Li, null Jia Wang, null Yanyu Jiang, null Qi Deng, null Jichun Shen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8229e692e930ae0d381c533c787d236
https://doi.org/10.1002/hon.2981/v2/response1
https://doi.org/10.1002/hon.2981/v2/response1
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high mortality, and there are no uniform guidelines for the treatment of this disease. Anti-CD19 chimeric antigen receptor (CAR) T cells show significant efficacy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3419831301e789031a7cb250792c87c
https://doi.org/10.3389/fonc.2021.726134
https://doi.org/10.3389/fonc.2021.726134
Publikováno v:
Future Generation Computer Systems. 99:143-153
Despite the advances made in developing human reliability analysis (HRA) methods, a gap remains between the methods developed by HRA researchers and the ways HRA practitioners actually use. Automated process control and control room operating supervi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b46787d08bf3dad670325fbd91f2407
https://doi.org/10.1016/j.future.2018.11.055
https://doi.org/10.1016/j.future.2018.11.055
Publikováno v:
Cancer Research. 82:5553-5553
With 1,279,000 new cases in 2020 and high incidence of relapse, hematologic cancers present significant opportunity for drug development. B-cell caners arise from various developmental stages of the B lymphocyte, and occur in several forms, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0020e66c487b34cf62110cfd56f98cf
https://doi.org/10.1158/1538-7445.am2022-5553
https://doi.org/10.1158/1538-7445.am2022-5553
Publikováno v:
Cancer Research. 81:1499-1499
Ras oncogenes (K/N/HRAS) are frequently mutated in 20% of all human cancers. Globally, approximately 3.4 million new cancer cases are diagnosed annually carrying Ras mutations. There is a large unmet medical need for treating cancers carrying Ras mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f009187de0fbf445f33672989b6e3d69
https://doi.org/10.1158/1538-7445.am2021-1499
https://doi.org/10.1158/1538-7445.am2021-1499
Autor:
Jijun Yuan
Publikováno v:
Cancer Research. 80:5652-5652
Abstract: CD73 is a cell surface enzyme that converts adenosine monophosphate to adenosine, a well-known immunosuppressive mediator that inhibits the cytotoxic function of T cells and natural killer cells. Tumors utilize this mechanism to escape atta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c592e928f97fbeff651628913f757d5d
https://doi.org/10.1158/1538-7445.am2020-5652
https://doi.org/10.1158/1538-7445.am2020-5652
Autor:
Lu Biao, Song Huang, Weikang Tao, Lianshan Zhang, Lei Zhang, Minsheng Zhang, Qiyue Hu, Hong Wan, Dan Wang, Jiayin Zhang, Ru Shen, Jijun Yuan, Jingsong Cao
Publikováno v:
Bioorganicmedicinal chemistry. 26(3)
A novel series of benzodihydrofuran derivatives was developed as potent MEK inhibitors through scaffold hopping based on known clinical compounds. Further SAR exploration and optimization led to another benzofuran series with good oral bioavailabilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5b5670026c3e84f707660c720f64018
https://pubmed.ncbi.nlm.nih.gov/29317148
https://pubmed.ncbi.nlm.nih.gov/29317148